Medicure Reports Financial Results for Quarter and Year Ended December 31, 2023
WINNIPEG, MB / ACCESSWIRE / April 8, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTCPINK:MCUJF), a company focused on...
Clinical Trial
Cantargia presents unique effects of nadunolimab in pancreatic cancer
LUND, SE / ACCESSWIRE / April 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented new...
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq’s Bid Price Requirement
Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrheaSAN FRANCISCO,...
DEA Faces Marijuana Legal Scrutiny: Hindering MMJ BioPharma Cultivation Marijuana Supply For Clinical Trials
Exposing the Secret: Federal Marijuana Production Remains NonexistentThe DEA Games Continue To Delay Legitimate Marijuana Clinical Trials and ResearchWASHINGTON, DC...
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
LA JOLLA, CA, April 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today...
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of...
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
Nuvectis Pharma’s NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTM Single Agent Antiproliferative Activity...
Supernus Provides Regulatory Update for SPN-830
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that...
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca...
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tractSAN DIEGO, April 08, 2024...
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
In combination with either atezolizumab or durvalumabMADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
MENLO PARK, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop...
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed...
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a...
Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024
Initial clinical data demonstrate a very high 85% overall response rate in patients with metastatic castrate-resistant prostate cancer. FORT LAUDERDALE,...